IE74205B1 - Xanthine derivatives having an adenosin-antagonist activity - Google Patents

Xanthine derivatives having an adenosin-antagonist activity

Info

Publication number
IE74205B1
IE74205B1 IE414789A IE414789A IE74205B1 IE 74205 B1 IE74205 B1 IE 74205B1 IE 414789 A IE414789 A IE 414789A IE 414789 A IE414789 A IE 414789A IE 74205 B1 IE74205 B1 IE 74205B1
Authority
IE
Ireland
Prior art keywords
substd
opt
alkyl
denotes
general formula
Prior art date
Application number
IE414789A
Other languages
English (en)
Other versions
IE894147L (en
Inventor
Ulrike Dr Kufner-Muhl
Karl-Heinz Dr Weber
Gerhard Dr Walther
Werner Dr Stransky
Helmut Dr Ensinger
Gunter Dr Schingnitz
Franz Josef Dr Kuhn
Erich Dr Lehr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IE894147L publication Critical patent/IE894147L/xx
Publication of IE74205B1 publication Critical patent/IE74205B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IE414789A 1988-12-22 1989-12-21 Xanthine derivatives having an adenosin-antagonist activity IE74205B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
IE894147L IE894147L (en) 1990-06-22
IE74205B1 true IE74205B1 (en) 1997-07-16

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
IE414789A IE74205B1 (en) 1988-12-22 1989-12-21 Xanthine derivatives having an adenosin-antagonist activity

Country Status (32)

Country Link
US (4) US5175291A (US20050026921A1-20050203-C00071.png)
EP (1) EP0374808B1 (US20050026921A1-20050203-C00071.png)
JP (1) JP2565576B2 (US20050026921A1-20050203-C00071.png)
KR (1) KR0165666B1 (US20050026921A1-20050203-C00071.png)
AT (1) ATE136897T1 (US20050026921A1-20050203-C00071.png)
BG (1) BG61669B2 (US20050026921A1-20050203-C00071.png)
BR (1) BR1100527A (US20050026921A1-20050203-C00071.png)
CA (1) CA2006387C (US20050026921A1-20050203-C00071.png)
CZ (1) CZ286230B6 (US20050026921A1-20050203-C00071.png)
DD (1) DD290421A5 (US20050026921A1-20050203-C00071.png)
DE (3) DE3843117A1 (US20050026921A1-20050203-C00071.png)
DK (1) DK652689A (US20050026921A1-20050203-C00071.png)
ES (1) ES2086313T3 (US20050026921A1-20050203-C00071.png)
FI (1) FI96513C (US20050026921A1-20050203-C00071.png)
GR (1) GR3019733T3 (US20050026921A1-20050203-C00071.png)
HR (1) HRP940724A2 (US20050026921A1-20050203-C00071.png)
HU (1) HU218674B (US20050026921A1-20050203-C00071.png)
IE (1) IE74205B1 (US20050026921A1-20050203-C00071.png)
IL (1) IL92829A (US20050026921A1-20050203-C00071.png)
MX (1) MX9203618A (US20050026921A1-20050203-C00071.png)
NO (1) NO173502C (US20050026921A1-20050203-C00071.png)
NZ (1) NZ231901A (US20050026921A1-20050203-C00071.png)
PH (2) PH31107A (US20050026921A1-20050203-C00071.png)
PL (1) PL162877B1 (US20050026921A1-20050203-C00071.png)
PT (1) PT92658B (US20050026921A1-20050203-C00071.png)
RU (1) RU2057752C1 (US20050026921A1-20050203-C00071.png)
SG (1) SG46380A1 (US20050026921A1-20050203-C00071.png)
SI (1) SI8912423B (US20050026921A1-20050203-C00071.png)
SK (1) SK279525B6 (US20050026921A1-20050203-C00071.png)
UA (1) UA26427A (US20050026921A1-20050203-C00071.png)
YU (1) YU47934B (US20050026921A1-20050203-C00071.png)
ZA (1) ZA899881B (US20050026921A1-20050203-C00071.png)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
GB2244487B (en) * 1990-05-29 1994-02-02 Ici Plc Azole derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (US20050026921A1-20050203-C00071.png) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
ES2120025T3 (es) * 1993-02-26 1998-10-16 Merrell Pharma Inc Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999062553A1 (fr) * 1998-06-01 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Medicaments contre la sterilite masculine
US6376521B1 (en) 1998-07-10 2002-04-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A3 adenosine receptor antagonists
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
NZ519427A (en) 1999-11-12 2003-08-29 Biogen Inc Polycycloalkylpurine derivative useful as an adenosine receptor antagonist
PL206890B1 (pl) * 1999-11-12 2010-10-29 Biogen Idec Ma Pochodna bicykloalkilopuryny, jej zastosowanie i kompozycja leku
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CN100467469C (zh) * 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
CA2516250A1 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
WO2004096228A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
ATE403656T1 (de) * 2003-05-06 2008-08-15 Cv Therapeutics Inc Xanthinderivate als a2b- adenosinrezeptorantagonisten
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
CN101094671A (zh) * 2004-04-16 2007-12-26 美国诺华卡迪亚公司 包含腺苷a1受体拮抗剂和醛固酮抑制剂的组合疗法
PT1789053E (pt) * 2004-09-01 2012-08-09 Gilead Sciences Inc Método de cicatrização de feridas utilizando antagonistas dos receptores de adenosina a2b
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
CN102015712A (zh) * 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
WO2011055391A1 (en) * 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES8401072A1 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia

Also Published As

Publication number Publication date
DD290421A5 (de) 1991-05-29
SG46380A1 (en) 1998-02-20
DE58909657D1 (de) 1996-05-23
ES2086313T3 (es) 1996-07-01
HRP940724A2 (en) 1997-06-30
CZ286230B6 (cs) 2000-02-16
FI96513C (fi) 1996-07-10
BR1100527A (pt) 2000-08-01
ZA899881B (en) 1991-08-28
NZ231901A (en) 1993-12-23
MX9203618A (es) 1992-09-01
IL92829A (en) 1995-12-31
PT92658A (pt) 1990-06-29
NO895168D0 (no) 1989-12-21
NO173502B (no) 1993-09-13
SK719789A3 (en) 1998-12-02
UA26427A (uk) 1999-08-30
NO895168L (no) 1990-06-25
PH31111A (en) 1998-02-23
ATE136897T1 (de) 1996-05-15
US5532368A (en) 1996-07-02
PL282878A1 (en) 1992-03-09
FI96513B (fi) 1996-03-29
HU218674B (hu) 2000-10-28
YU47934B (sh) 1996-05-20
CZ719789A3 (cs) 1999-10-13
HU896736D0 (en) 1990-02-28
PT92658B (pt) 1995-09-12
US5688802A (en) 1997-11-18
SK279525B6 (sk) 1998-12-02
RU2057752C1 (ru) 1996-04-10
DK652689D0 (da) 1989-12-21
GR3019733T3 (en) 1996-07-31
HUT52503A (en) 1990-07-28
IE894147L (en) 1990-06-22
US5175291A (en) 1992-12-29
PH31107A (en) 1998-02-23
KR0165666B1 (ko) 1999-01-15
JPH02247180A (ja) 1990-10-02
NO173502C (no) 1993-12-22
CA2006387A1 (en) 1990-06-22
AU637990B2 (en) 1993-06-17
KR900009646A (ko) 1990-07-05
PL162877B1 (pl) 1994-01-31
YU242389A (en) 1991-10-31
CA2006387C (en) 2000-02-08
EP0374808B1 (de) 1996-04-17
DE3843117A1 (de) 1990-06-28
DE8817122U1 (de) 1993-02-04
DK652689A (da) 1990-06-23
BG61669B2 (bg) 1998-02-27
US5696124A (en) 1997-12-09
EP0374808A3 (de) 1991-05-15
AU4707289A (en) 1990-06-28
SI8912423B (sl) 1998-12-31
IL92829A0 (en) 1990-09-17
FI896117A0 (fi) 1989-12-20
JP2565576B2 (ja) 1996-12-18
EP0374808A2 (de) 1990-06-27
SI8912423A (sl) 1998-04-30

Similar Documents

Publication Publication Date Title
IE74205B1 (en) Xanthine derivatives having an adenosin-antagonist activity
US5641784A (en) 8-substituted 1,3-dialiphaticxanthine derivatives
CA2028235C (en) Condensed purine derivatives
US5525607A (en) Xanthine compounds
SK18595A3 (en) Asymetrically substituted xanthine with adenosineantagonistic properties
EP1230241B1 (en) Adenosine receptor antagonists and methods of making and using the same
AU632914B2 (en) Selective adenosine receptor agents
NO146775B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive racemiske eller optisk aktive kondenserte pyrimidinderivater
US4232155A (en) Purine compounds
HU183234B (en) Process for the enantioselective synthesis of optically active cys-14-oxo-e-homo-eburnan
US4269839A (en) Alkylthio-adenines used as bronchodilators
IT9020715A1 (it) Derivati diesteri di ottaidro-indolo/2, 3-a/chinolizina e loro sali nonche' procedimento per la loro preparazione
GB2056448A (en) Purine Bronchodilators
AU2006200846A1 (en) Adenosine Receptor Antagonists and Methods of Making and Using the Same

Legal Events

Date Code Title Description
MM4A Patent lapsed